Pharmaceuticals in Denmark
Datamonitor, January 2011, Pages: 44
The Pharmaceuticals in Denmark industry profile is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.
Scope
- Contains an executive summary and data on value, volume and/or segmentation
- Provides textual analysis of Pharmaceuticals in Denmark’s recent performance and future prospects
- Incorporates in-depth five forces competitive environment analysis and scorecards
- Includes a five-year forecast of Pharmaceuticals in Denmark
- The leading companies are profiled with supporting key financial metrics
- Supported by the key macroeconomic and demographic data affecting the market
Highlights
- Detailed information is included on market size, measured by value and/or volume
- Five forces scorecards provide an accessible yet in depth view of the market’s competitive landscape
- Market shares are covered by manufacturer or brand
Why you should buy this report
- Spot future trends and developments
- Inform your business decisions
- Add weight to presentations and marketing materials
- Save time carrying out entry-level research
Market Definition
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant annual average exchange rates. For the purpose of this report Europe is deemed to comprise of Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, the Ukraine and the United Kingdom.
EXECUTIVE SUMMARY
MARKET OVERVIEW
Market definition
Research highlights
Market analysis
MARKET VALUE
MARKET SEGMENTATION I
MARKET SEGMENTATION II
MARKET SHARE
FIVE FORCES ANALYSIS
Summary
Buyer power
Supplier power
New entrants
Substitutes
Rivalry
LEADING COMPANIES
GlaxoSmithKline Plc
Nycomed International Management GmbH
Orifarm Group
Pfizer Inc.
MARKET FORECASTS
Market value forecast
MACROECONOMIC INDICATORS
APPENDIX
Methodology
Industry associations
Related Datamonitor research
Disclaimer
ABOUT DATAMONITOR
Premium Reports
Summary Reports
Datamonitor consulting
LIST OF TABLES
Table 1: Denmark pharmaceuticals market value: $ billion, 2006–10(e)
Table 2: Denmark pharmaceuticals market segmentation I:% share, by value, 2010(e)
Table 3: Denmark pharmaceuticals market segmentation II: % share, by value, 2010(e)
Table 4: Denmark pharmaceuticals market share: % share, by value, 2010(e)
Table 5: GlaxoSmithKline Plc: key facts
Table 6: GlaxoSmithKline Plc: key financials ($)
Table 7: GlaxoSmithKline Plc: key financials (£)
Table 8: GlaxoSmithKline Plc: key financial ratios
Table 9: Nycomed International Management GmbH: key facts
Table 10: Nycomed International Management GmbH: key financials ($)
Table 11: Nycomed International Management GmbH: key financials (€)
Table 12: Nycomed International Management GmbH: key financial ratios
Table 13: Orifarm Group: key facts
Table 14: Orifarm Group: key financials ($)
Table 15: Orifarm Group: key financials (DKK)
Table 16: Orifarm Group: key financial ratios
Table 17: Pfizer Inc.: key facts
Table 18: Pfizer Inc.: key financials ($)
Table 19: Pfizer Inc.: key financial ratios
Table 20: Denmark pharmaceuticals market value forecast: $ billion, 2010–15
Table 21: Denmark size of population (million), 2006–10
Table 22: Denmark GDP (constant 2000 prices, $ billion), 2006–10
Table 23: Denmark GDP (current prices, $ billion), 2006–10
Table 24: Denmark inflation, 2006–10
Table 25: Denmark consumer price index (absolute), 2006–10
Table 26: Denmark exchange rate, 2006–10
LIST OF FIGURES
Figure 1: Denmark pharmaceuticals market value: $ billion, 2006–10(e)
Figure 2: Denmark pharmaceuticals market segmentation I:% share, by value, 2010(e)
Figure 3: Denmark pharmaceuticals market segmentation II: % share, by value, 2010(e)
Figure 4: Denmark pharmaceuticals market share: % share, by value, 2010(e)
Figure 5: Forces driving competition in the pharmaceuticals market in Denmark, 2010
Figure 6: Drivers of buyer power in the pharmaceuticals market in Denmark, 2010
Figure 7: Drivers of supplier power in the pharmaceuticals market in Denmark, 2010
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Denmark, 2010
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Denmark, 2010
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Denmark, 2010
Figure 11: GlaxoSmithKline Plc: revenues & profitability
Figure 12: GlaxoSmithKline Plc: assets & liabilities
Figure 13: Nycomed International Management GmbH: revenues & profitability
Figure 14: Nycomed International Management GmbH: assets & liabilities
Figure 15: Orifarm Group: revenues & profitability
Figure 16: Orifarm Group: assets & liabilities
Figure 17: Pfizer Inc.: revenues & profitability
Figure 18: Pfizer Inc.: assets & liabilities
Figure 19: Denmark pharmaceuticals market value forecast: $ billion, 2010–15
- AstraZeneca A/S
- Nycomed Danmark A/S
- Orifarm A/S
- Pfizer A/S
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
